Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148681 · ClinicalTrials.gov registry record · Phase 2
Preoperative Herceptin and Navelbine for Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00148681 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 49 participants.
The verdict
NCT00148681, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Herceptin
- DRUG Navelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2001-05 |
| Est. Completion | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00148681
The ClinicalTrials.gov registry entry for NCT00148681 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00148681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00148681 about?
NCT00148681 is a clinical study titled "Preoperative Herceptin and Navelbine for Breast Cancer". The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
What is the current status of trial NCT00148681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2001-05. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00148681?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Herceptin (DRUG), Navelbine (DRUG).
Who is sponsoring clinical trial NCT00148681?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.